Bristol Myers Squibb Gross Margin 2010-2023 | BMY

Current and historical gross margin for Bristol Myers Squibb (BMY) over the last 10 years. The current gross profit margin for Bristol Myers Squibb as of March 31, 2023 is %.
Bristol Myers Squibb Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2023-03-31 $45.85B $35.62B 77.68%
2022-12-31 $46.16B $36.02B 78.04%
2022-09-30 $46.74B $36.84B 78.82%
2022-06-30 $47.14B $37.31B 79.13%
2022-03-31 $46.96B $37.39B 79.62%
2021-12-31 $46.39B $36.45B 78.57%
2021-09-30 $45.47B $34.97B 76.92%
2021-06-30 $44.38B $33.68B 75.88%
2021-03-31 $42.81B $31.86B 74.42%
2020-12-31 $42.52B $30.75B 72.31%
2020-09-30 $39.40B $28.04B 71.18%
2020-06-30 $34.86B $24.22B 69.47%
2020-03-31 $31.01B $21.09B 68.02%
2019-12-31 $26.15B $18.07B 69.10%
2019-09-30 $24.17B $16.98B 70.23%
2019-06-30 $23.86B $16.80B 70.43%
2019-03-31 $23.29B $16.58B 71.20%
2018-12-31 $22.56B $16.09B 71.34%
2018-09-30 $22.04B $15.58B 70.69%
2018-06-30 $21.60B $15.21B 70.42%
2018-03-31 $21.04B $14.71B 69.90%
2017-12-31 $20.78B $14.76B 71.05%
2017-09-30 $20.57B $14.75B 71.71%
2017-06-30 $20.24B $14.69B 72.60%
2017-03-31 $19.97B $14.78B 74.04%
2016-12-31 $19.43B $14.46B 74.42%
2016-09-30 $18.47B $13.96B 75.56%
2016-06-30 $17.62B $13.31B 75.55%
2016-03-31 $16.91B $12.80B 75.67%
2015-12-31 $16.56B $12.65B 76.39%
2015-09-30 $16.53B $12.61B 76.27%
2015-06-30 $16.38B $12.55B 76.60%
2015-03-31 $16.11B $12.30B 76.34%
2014-12-31 $15.88B $11.95B 75.24%
2014-09-30 $16.06B $11.82B 73.61%
2014-06-30 $16.21B $11.80B 72.81%
2014-03-31 $16.37B $11.84B 72.36%
2013-12-31 $16.39B $11.77B 71.81%
2013-09-30 $16.14B $11.71B 72.60%
2013-06-30 $15.81B $11.57B 73.22%
2013-03-31 $16.20B $11.83B 73.03%
2012-12-31 $17.62B $13.01B 73.84%
2012-09-30 $18.88B $13.98B 74.04%
2012-06-30 $20.49B $15.17B 74.03%
2012-03-31 $21.48B $15.93B 74.13%
2011-12-31 $21.24B $15.65B 73.65%
2011-09-30 $20.90B $15.26B 72.99%
2011-06-30 $20.35B $14.84B 72.89%
2011-03-31 $19.69B $14.37B 73.01%
2010-12-31 $19.48B $14.21B 72.92%
2010-09-30 $19.41B $14.11B 72.71%
2010-06-30 $19.40B $14.06B 72.50%
2010-03-31 $19.29B $14.01B 72.63%
2009-12-31 $18.81B $13.67B 72.67%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $135.883B $46.159B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
GSK (GSK) United Kingdom $69.205B 9.66
Bio-Rad Laboratories (BIO.B) United States $11.071B 29.60
QIAGEN (QGEN) Netherlands $10.425B 22.01
Ginkgo Bioworks Holdings (DNA) United States $3.504B 0.00
Arcus Biosciences (RCUS) United States $1.484B 0.00
Biohaven (BHVN) United States $1.414B 0.00
Emergent Biosolutions (EBS) United States $0.414B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.183B 0.00
Enzo Biochem (ENZ) United States $0.109B 0.00
SQZ Biotechnologies (SQZ) United States $0.017B 0.00